Kronman Matthew P, Gerber Jeffrey S, Prasad Priya A, Adler Amanda L, Bass Julie A, Newland Jason G, Shah Kavisha M, Zerr Danielle M, Feng Rui, Coffin Susan E, Zaoutis Theoklis E
Division of Infectious Diseases, Seattle Children's Hospital, University of Washington School of Medicine
Division of Infectious Diseases, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine.
J Pediatric Infect Dis Soc. 2012 Dec;1(4):306-13. doi: 10.1093/jpids/pis053. Epub 2012 Jul 3.
Antibiotics are often given for inflammatory bowel disease (IBD) exacerbations, but their use among pediatric inpatients has not been assessed. We aimed to validate administrative data for identifying hospitalizations for IBD exacerbation and to characterize antibiotic use for IBD exacerbations across children's hospitals.
To validate administrative data for identifying IBD exacerbation, we reviewed charts of 409 patients with IBD at 3 US tertiary care children's hospitals. Using the case definition with optimal test characteristics, we identified 3450 children with 5063 hospitalizations for IBD exacerbation at 36 children's hospitals between January 1, 2007 and December 31, 2009, excluding those with diagnosis codes for specific bacterial infections. We estimated predicted and expected hospital-specific antibiotic utilization rates using mixed-effects logistic regression, adjusting for patient- and hospital-level factors.
Administrative codes for receipt of intravenous steroids or endoscopy provided 79% positive predictive value and 71% sensitivity for identifying hospitalizations for IBD exacerbation. Antibiotics were administered for ≥2 of the first 3 hospital days during 40.7% of IBD exacerbations in US children's hospitals; however, the proportion of patients receiving antibiotics varied significantly across hospitals from 27% to 71% (P < .001), despite adjustment for several patient- and hospital-level variables. Among those given antibiotics, the 3 most common regimens were metronidazole alone (26.9%), metronidazole with ciprofloxacin (10.3%), and ampicillin with gentamicin and metronidazole (7.0%).
Significant variability exists in antibiotic use for children hospitalized with IBD exacerbation, which is unexplained by disease severity or hospital volume. Further study should determine the optimal antibiotic therapy for this condition.
抗生素常用于炎症性肠病(IBD)的病情加重期,但尚未对儿科住院患者中抗生素的使用情况进行评估。我们旨在验证用于识别IBD病情加重导致住院的管理数据,并描述儿童医院中IBD病情加重时抗生素的使用特征。
为了验证用于识别IBD病情加重的管理数据,我们回顾了美国3家三级医疗儿童医院中409例IBD患者的病历。使用具有最佳检测特征的病例定义,我们在2007年1月1日至2009年12月31日期间,在36家儿童医院中识别出3450名因IBD病情加重而住院5063次的儿童,不包括那些具有特定细菌感染诊断代码的患者。我们使用混合效应逻辑回归估计预测的和预期的医院特定抗生素使用率,并对患者和医院层面的因素进行调整。
接受静脉注射类固醇或内镜检查的管理代码对识别IBD病情加重导致的住院具有79%的阳性预测值和71%的敏感性。在美国儿童医院中,40.7%的IBD病情加重患儿在住院的前3天中至少有2天使用了抗生素;然而,尽管对几个患者和医院层面的变量进行了调整,但各医院接受抗生素治疗的患者比例差异很大,从27%到71%(P <.001)。在使用抗生素的患者中,3种最常见的治疗方案分别是单独使用甲硝唑(26.9%)、甲硝唑与环丙沙星联用(10.3%)以及氨苄西林与庆大霉素和甲硝唑联用(7.0%)。
因IBD病情加重而住院的儿童在抗生素使用方面存在显著差异,这种差异无法用疾病严重程度或医院规模来解释。进一步的研究应确定针对这种情况的最佳抗生素治疗方案。